Cargando…

Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis

BACKGROUND: Tumor necrosis factor receptor-associated factor 6 (TRAF6) can regulate the activation of inflammatory signaling pathways by acting as an E3 ubiquitin ligase, which enhances B cell activation. This study aimed to evaluate the expression of TRAF6 in the peripheral blood B cells of myasthe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Li, Yue, Li, Jia-Wen, Qin, Ying-Hui, Zhai, Hui, Feng, Bin, Li, He, Zhang, Ning-Nannan, Yang, Chun-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382794/
https://www.ncbi.nlm.nih.gov/pubmed/35978310
http://dx.doi.org/10.1186/s12883-022-02833-9
_version_ 1784769358683176960
author Li, Ting
Li, Yue
Li, Jia-Wen
Qin, Ying-Hui
Zhai, Hui
Feng, Bin
Li, He
Zhang, Ning-Nannan
Yang, Chun-Sheng
author_facet Li, Ting
Li, Yue
Li, Jia-Wen
Qin, Ying-Hui
Zhai, Hui
Feng, Bin
Li, He
Zhang, Ning-Nannan
Yang, Chun-Sheng
author_sort Li, Ting
collection PubMed
description BACKGROUND: Tumor necrosis factor receptor-associated factor 6 (TRAF6) can regulate the activation of inflammatory signaling pathways by acting as an E3 ubiquitin ligase, which enhances B cell activation. This study aimed to evaluate the expression of TRAF6 in the peripheral blood B cells of myasthenia gravis (MG) patients and analyze the relationships between TRAF6 expression and clinical characteristics. METHOD: In our study, the expression level of TRAF6 in peripheral blood B cells of 89 patients was measured by flow cytometry compared with that of healthy subjects. The effects of disease severity, MG classification and immunotherapy on TRAF6 expression level were also analyzed. RESULTS: In our study, TRAF6 expression was elevated in CD19(+) B cells and CD19(+)CD27(+) memory B cells in generalized MG (GMG) patients compared with ocular MG (OMG) patients (p = 0.03 and p = 0.03, respectively). There was a significant positive correlation between the TRAF6 expression level and disease severity in both OMG patients and GMG patients (CD19(+) B cells: OMG: p < 0.001, r = 0.89; GMG: p = 0.001, r = 0.59; CD29(+)CD27(+) B cells: OMG: p = 0.001, r = 0.80; GMG: p = 0.048, r = 0.38). TRAF6 expression was significantly elevated in CD19(+) B cells and CD19(+)CD27(+) memory B cells in GMG with acute aggravation compared with GMG in MMS (p = 0.009 and p = 0.028, respectively). In the eleven MG patients who were followed, TRAF6 expression in B cells and memory B cells was significantly decreased after treatment (p = 0.03 and p < 0.01, respectively). CONCLUSION: TRAF6 is potentially a useful biomarker of inflammation in patients with MG, and might be used to evaluate the effectiveness of treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-022-02833-9.
format Online
Article
Text
id pubmed-9382794
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93827942022-08-18 Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis Li, Ting Li, Yue Li, Jia-Wen Qin, Ying-Hui Zhai, Hui Feng, Bin Li, He Zhang, Ning-Nannan Yang, Chun-Sheng BMC Neurol Research BACKGROUND: Tumor necrosis factor receptor-associated factor 6 (TRAF6) can regulate the activation of inflammatory signaling pathways by acting as an E3 ubiquitin ligase, which enhances B cell activation. This study aimed to evaluate the expression of TRAF6 in the peripheral blood B cells of myasthenia gravis (MG) patients and analyze the relationships between TRAF6 expression and clinical characteristics. METHOD: In our study, the expression level of TRAF6 in peripheral blood B cells of 89 patients was measured by flow cytometry compared with that of healthy subjects. The effects of disease severity, MG classification and immunotherapy on TRAF6 expression level were also analyzed. RESULTS: In our study, TRAF6 expression was elevated in CD19(+) B cells and CD19(+)CD27(+) memory B cells in generalized MG (GMG) patients compared with ocular MG (OMG) patients (p = 0.03 and p = 0.03, respectively). There was a significant positive correlation between the TRAF6 expression level and disease severity in both OMG patients and GMG patients (CD19(+) B cells: OMG: p < 0.001, r = 0.89; GMG: p = 0.001, r = 0.59; CD29(+)CD27(+) B cells: OMG: p = 0.001, r = 0.80; GMG: p = 0.048, r = 0.38). TRAF6 expression was significantly elevated in CD19(+) B cells and CD19(+)CD27(+) memory B cells in GMG with acute aggravation compared with GMG in MMS (p = 0.009 and p = 0.028, respectively). In the eleven MG patients who were followed, TRAF6 expression in B cells and memory B cells was significantly decreased after treatment (p = 0.03 and p < 0.01, respectively). CONCLUSION: TRAF6 is potentially a useful biomarker of inflammation in patients with MG, and might be used to evaluate the effectiveness of treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-022-02833-9. BioMed Central 2022-08-17 /pmc/articles/PMC9382794/ /pubmed/35978310 http://dx.doi.org/10.1186/s12883-022-02833-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Ting
Li, Yue
Li, Jia-Wen
Qin, Ying-Hui
Zhai, Hui
Feng, Bin
Li, He
Zhang, Ning-Nannan
Yang, Chun-Sheng
Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
title Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
title_full Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
title_fullStr Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
title_full_unstemmed Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
title_short Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis
title_sort expression of traf6 in peripheral blood b cells of patients with myasthenia gravis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382794/
https://www.ncbi.nlm.nih.gov/pubmed/35978310
http://dx.doi.org/10.1186/s12883-022-02833-9
work_keys_str_mv AT liting expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis
AT liyue expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis
AT lijiawen expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis
AT qinyinghui expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis
AT zhaihui expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis
AT fengbin expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis
AT lihe expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis
AT zhangningnannan expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis
AT yangchunsheng expressionoftraf6inperipheralbloodbcellsofpatientswithmyastheniagravis